Acute encephalitis syndrome and Japanese encephalitis in India: insights from a nationally representative laboratory surveillance network, 2014–2023 Authors: Rizwan Suliankatchi Abdulkader, Sabarinathan Ramasamy, Raman Swathy Vaman, Gajanan N Sapkal, Jitendra Narayan, Neetu Vijay, Vanessa Ravel, Sinthanai Selvan Palanisamy, Gururaj Rao Deshpande, Nivedita Gupta, Manoj V Murhekar, VRDLN Published: 2025 ABSTRACT AbstractBackgroundAcute Encephalitis Syndrome (AES) is a critical public health issue, contributing significantly to morbidity and mortality in India, particularly among children. Despite ongoing vaccination efforts, Japanese Encephalitis (JE) remains a major cause of AES. This study analyzes the epidemiology of AES and JE in India from 2014 to 2023, using data from the Virus Research and Diagnostic Laboratory Network (VRDLN).MethodsA cross-sectional analysis was conducted on AES cases reported by 159 VRDLN laboratories between 2014 and 2023. Standardized diagnostic tests such as polymerase chain reaction were used to identify causative pathogens, including JE virus. All the labs in the network followed BSL-2 standards. Descriptive analyses were performed on AES cases by year, etiology, and demographic factors. JE cases were further analyzed for geographic distribution, age, sex, and clinical characteristics.ResultsOver the study period, 124,890 AES cases were reported, with 16.3% testing positive for at least one pathogen, including 10% confirmed as JE. The highest JE positivity was observed in the northeastern states. An increasing trend in the number of cases tested and JE detections was noted, alongside a shift in the age distribution towards younger populations. The median (IQR) annual test positivity for JEV among tested was 16.2% (14.5%, 18.4%).ConclusionsThe VRDLN has substantially enhanced India’s capacity to diagnose and monitor AES and JE. Despite progress, JE transmission persists, particularly in endemic regions, posing significant public health challenges. Strengthened surveillance, improved diagnostic coverage, and integrated pathogen testing are essential for effective interventions. Targeted strategies and sustained public health efforts are critical to reducing the burden of AES and JE in India.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12879-025-12274-7.Keywords: Acute encephalitis syndrome, Japanese encephalitis, Virus research and diagnostic laboratory network, Surveillance, Epidemiology, India Background Acute encephalitis syndrome (AES) is defined as “an illness characterized by the acute onset of fever, accompanied by altered consciousness, stupor, coma, and/or new-onset seizures, excluding simple febrile seizures” [1]. AES represents a significant public health challenge, causing substantial morbidity, mortality, and long-term neurological complications in both children and adults. Globally, AES accounted for an estimated 90,000 deaths and 4.8 million disability-adjusted life years (DALYs) in 2019 [2]. The etiology of AES is diverse, involving several viral, bacterial, fungal, and parasitic pathogens with distinct epidemiological profiles and geographic distributions. Viral causes include pathogens such as Japanese encephalitis virus (JEV), West Nile virus, enteroviruses, dengue virus, herpes simplex virus, varicella-zoster virus, Epstein-Barr virus, Nipah virus, and Chandipura virus. Bacterial pathogens include Rickettsia, Spirochaetes, Listeria, and Leptospira, while parasitic agents such as Plasmodium (malaria), Naegleria fowleri, and fungi like Cryptococcus and Histoplasma have also been implicated [3]. Among these, JEV is globally recognized as the most common cause of AES in children [4]. JEV, a vector-borne flavivirus, is associated with a case fatality rate of 5–30%, and 30–50% of survivors experience long-term neuropsychiatric sequelae [5]. Recent outbreaks of Nipah virus, Chandipura virus, and Naegleria fowleri in India have highlighted the urgent need for better understanding and control of AES. In India, approximately 11,000 AES cases and 1,200 deaths are reported annually, although these figures are likely underestimates, as captured by the Integrated Disease Surveillance Programme (IDSP) [6]. Studies across various regions in India have reported pathogen detection rates ranging from 17% to 72% among AES patients [7–10]. Of the reported AES cases, 14–18% are attributed to JEV [11]. A large-scale study in India involving 10,107 AES cases identified JEV, Orientia tsutsugamushi (scrub typhus), and dengue virus as the most common causative agents [12]. JEV was first detected in India in 1952, followed by multiple outbreaks and widespread transmission across states and districts. In response, India initiated JEV vaccination campaigns between 2006 and 2011, integrating the JEV vaccine into the routine immunization schedule in endemic regions by 2013 [13]. Despite extensive vaccination efforts, the incidence of JEV-related AES has not significantly declined, and several outbreaks in recent years have raised concerns about ongoing transmission [14]. However, vaccination programs have demonstrated localized impacts, reducing incidence in endemic areas and shifting the age distribution of JEV cases in India [13, 15]. To enhance diagnostic capacity and strengthen public health responses, the Virus Research and Diagnostic Laboratory Network (VRDLN) was established under the Department of Health Research, Ministry of Health and Family Welfare. This network aims to ensure timely diagnosis of viral diseases of clinical and public health importance. This study analyzes the largest comprehensive data on AES and JE surveillance in India, spanning nearly a decade. Unlike previous surveillance studies, which were often region-specific or based on smaller sample size, our study leverages data from a nationwide laboratory network (VRDLN), allowing for a more robust assessment of temporal trends, geographic variations, and diagnostic patterns. In this study, we describe the epidemiological trends of AES and JE cases reported in India from 2014 to 2023 through the VRDLN. Methods Study design This cross-sectional study analyzed laboratory surveillance data from the Virus Research and Diagnostic Laboratory Network (VRDLN) collected between 2014 and 2023. Study population The study population comprised all AES cases referred to the Virus Research and Diagnostic Laboratories (VRDLs) during the study period. Data source The VRDLs are district- and state-level laboratories operating under the VRDLN, established by the Department of Health Research, Ministry of Health & Family Welfare, Government of India. During the study period, 159 VRDLs were operational across India. These laboratories collect patient data using a standardized case report form that includes clinical and epidemiological details, sample collection information, laboratory tests performed, and their results. The VRDLs process clinical samples from both outpatients and inpatients in medical college hospitals, as well as samples from suspected disease outbreaks referred by state health authorities [16]. Data routinely collected by the VRDLN were utilized for this analysis. Laboratory methods The VRDLs follow a standardized testing algorithm and employ diagnostic methods such as enzyme-linked immunosorbent assay (ELISA) for detecting viral pathogens. These laboratories are equipped to test for more than 70 pathogens using established protocols. Throughout the study period, in-house National Institute of Virology (NIV) JE IgM kit, commercial IgM ELISA kits complaint with ISO 13,485 were used, which had their specificity and sensitivity validated through clinical studies, as documented in their respective kit inserts [17, 18]. The NIV JE IgM Capture ELISA kit was used to detect IgM antibodies in serum and cerebrospinal fluid (CSF) [19]. The samples were diluted (serum − 1:100, CSF − 1:10) as per the protocol, while controls were used undiluted. Anti-human IgM-coated strips were washed, and 50 µL of samples and controls were added to the wells. Plates were incubated in the dark at 37 °C for 1 h. Wells were then sequentially treated with JE antigen, biotin-labelled anti-JE monoclonal antibody, and avidin-horseradish peroxidase (HRP), with appropriate incubations and washes. Tetramethylbenzidine (TMB) substrate was added, and the plate was incubated at room temperature for 10 min. Reaction was stopped with 1 N H2SO4, and absorbance was measured at 450 nm. Quality assurance practices The VRDLs follow protocol tested and approved by National Institute of Virology, Pune which complies with ISO 15189:2012 standard. Currently, labs are transitioning to ISO 15189:2022 standard. Strict biosafety protocols and workflow segregation were followed to maintain quality control. Protocols were followed during sample collection and transport, ensuring that samples were maintained at a temperature of 2–8 °C.Additionally, reagents were not brought to room temperature during testing to preserve their integrity. To ensure accurate and reliable results, the microplate reader was periodically calibrated in accordance with the manufacturer’s recommendations. The External Quality Assurance (EQA) program for Japanese Encephalitis (JE) virus assessed the diagnostic accuracy of VRDLs. A panel of six blinded serum samples (two positives, four negatives) was prepared, validated, and distributed on dry ice. Laboratories used JE IgM Capture ELISA kits from ICMR-NIV, Pune, following standardized protocols. Results were evaluated against reference values, assessing concordance, sensitivity, and interlaboratory variation. Labs with < 90% concordance underwent retesting and corrective measures. Continuous monitoring, training, and periodic EQA programs are conducted to maintain diagnostic quality. Operational definition AES was defined as the acute onset of fever accompanied by altered mental status (e.g., confusion, disorientation, coma, or inability to talk) and/or new-onset seizures in individuals of any age [1]. A case of Japanese encephalitis (JE) was defined as the detection of IgM antibodies against JEV in either serum or cerebrospinal fluid (CSF) of a patient with AES. Data analysis De-identified data were extracted from the VRDL database following a standardized process to ensure accuracy and consistency. The raw dataset was first screened for completeness and structural integrity, checking for missing values, duplicate entries, and inconsistencies in key variables such as age, district, date of sample collection, and test results. For missing data, we employed appropriate imputation methods to address gaps in age and district, as detailed in Fig. 1. Specifically, age was imputed using median values within similar demographic and epidemiological strata, while missing district information was inferred based on laboratory location. AES cases were categorized by year and etiology. A subset of AES cases positive for Japanese encephalitis (JE) was further analyzed based on year, geographic location (district, state, and laboratory zone), demographic characteristics (age group and sex), and clinical features. Data cleaning workflow for the VRDLN lab network in India To assess the spatial distribution of JE cases, the study period was divided into two intervals: 2014–2018 and 2019–2023. Percent positivity for JE was compared across these intervals, with 2018 selected as the median year to facilitate comparative analysis. Categorical variables were summarized as proportions. To account for the effects of seasonality and the expansion of the number of labs in the network, we modelled the tested counts, positive counts and test positivity using a time-series approach, in which seasonal-trend decomposition based on Loess was applied to the data after taking the ratio of the monthly counts to the number of reporting labs. This approach removed the effect of the seasonality and normalised the data for number of labs. We created time series plots to compare the adjusted and observed results. We performed statistical analyses using R (version 4.3.1). We used the fuzzyjoin package for imputing and cleaning district codes, ggplot2 for visualization and stats for time series modelling. We used QGIS (version 3.34.8). for generating choropleth maps using shapefiles downloaded from the Survey of India website [20]. Results Description of AES cases The number of operational VRDLs in India increased significantly, from 20 in 2014 to 159 in 2023, covering 413 districts, including 60 JE-endemic districts. During this period, 1,24,890 AES cases were diagnosed across the network, with 20,376 (16.3%) cases testing positive for at least one pathogen. The number of AES cases tested annually increased from 4,607 in 2014 to 24,244 in 2019, while the test positivity rates ranged from 11.4% in 2014 to a peak of 20% in 2019 (Table 1). Table 1Year-wise distribution of AES cases from 2014–2023, India (N = 1,24,890)YearNo. of AES patients tested for any pathogen (n*)Number positive for any pathogen (n%)20144,607526 (11.4)20157,2191,043 (14.4)20169,5501,360 (14.2)201710,1131,209 (12)201815,5082,827 (18.2)201924,2444,843 (20)20207,5401,310 (17.4)202110,5761,631 (15.4)202214,8602,436 (16.4)202320,6733,191 (15.4) Overall 1,24,89020,376 (16.3)*n denotes numbers Year-wise distribution of AES cases from 2014–2023, India (N = 1,24,890) *n denotes numbers Among the total AES cases tested, 65,066 (52.1%) were tested for JE, 58,669 (47%) for herpes simplex virus, and 30,551 (24.5%) for dengue virus. The positivity rates for specific pathogens were as follows: Measles virus (21.3%), Dengue virus (14%), Chikungunya virus (13.7%), JE (10%), Cytomegalovirus (7%), Epstein-Barr virus (4.8%), Herpes Simplex virus (2.8%), Varicella-Zoster virus (2.5%), Enteroviruses (1.5%), and West Nile virus (0.8%). We were able to detect causative pathogens in 16.72% of AES cases. (Table 2). Table 2Common etiologies of AES tested in VRDLNs from 2014-23, India (N = 1,24,890)PathogenNumber testedNumber positive (%)Japanese Encephalitis virus65,0666,554 (10)Herpes Simplex virus58,6691,646 (2.8)Dengue virus30,5514,293 (14)Cytomegalovirus30,0592,093 (7)Enterovirus23,919361 (1.5)Epstein–Barr virus21,6301,027 (4.8)Varicella Zoster virus20,527511 (2.5)Chikungunya virus13,8971,897 (13.7)West Nile virus9,58874 (0.8)Measles2,091446 (21.3)Note: Multiple responses are possible Common etiologies of AES tested in VRDLNs from 2014-23, India (N = 1,24,890) Note: Multiple responses are possible In addition to 65,066 AES cases tested for JE, 7,483 clinician-suspected samples without AES symptoms were also tested for JE, with 876 (11.7%) testing positive. Several co-infections were identified among AES patients, with the JE-dengue virus combination being the most common (4.3%), followed by JE-chikungunya/dengue (1.5%), JE-chikungunya (1%), JE-herpes simplex virus (0.5%), and JE-scrub typhus (0.4%). (Fig. 2). Co-infection patterns of aetiological agents among AES, VRDLN, India, 2014–2023 Description of JE cases Time distribution Between 2014 and 2023, 65,066 patients were tested for JEV across 62 VRDLs in 76 endemic districts of India. The annual number of patients tested increased from 2,120 in 2014 to 16,181 in 2019. The median (IQR) annual positivity rate for JEV among tested patients was 16.2% (14.5%–18.4%) (Table 3). Table 3JE positivity from 2014–2023, VRDLN, India (N = 65,066)YearsTotal no of VRDLs (n*)No. of VRDLs testing for (n)No. of districts covered (n)No. of JE endemic districts covered (n)No. of persons tested for JE (n)No. of persons positive for JE n (%)20142013201472,120284 (13.4)20152017279433,928654 (16.65)20164222327595,482705 (12.86)20174326292523,783545 (14.41)201810538419619,8821,748 (17.69)2019105624717116,1813,202 (19.79)202011849356625,190965 (18.59)202113142325584,959972 (19.6)202214454361765,235771 (14.73)202315962413608,3061,314 (15.82)*n denotes numbers JE positivity from 2014–2023, VRDLN, India (N = 65,066) *n denotes numbers Place distribution Testing coverage and JE positivity improved during 2014–2023, with 21,931 (34%) samples originating from northern zone laboratories, followed by the northeast zone with 16,054 (25%). The highest positivity rates were observed in the northeast zone (21.2%) (Fig. 3). District-level test positivity for JE, VRDLN, India, 2014–2023 (N = 65,066) In the eastern zone, districts such as Khordha (Odisha), Giridih, Hazaribagh, Ranchi (Jharkhand), and Patna (Bihar) reported the highest percent positivity. In the northeast zone, districts including West Tripura, Sepahijala, Gomati (Tripura), Lakhimpur (Assam), and East Khasi Hills (Meghalaya) consistently showed high JE positivity. In the western zone, districts such as Chandrapur, Nagpur, Chhatrapati Sambhajinagar, Hingoli, and Gadchiroli (Maharashtra) had the highest positivity rates. In the northern zone, districts including Jodhpur (Rajasthan), Karnal, Yamunanagar, Ambala (Haryana), and Shimla (Himachal Pradesh) reported elevated positivity rates. The central zone saw the highest positivity in districts such as Lucknow, Sitapur, Bahraich, Gonda, and Hardoi (Uttar Pradesh). In the southern zone, Chennai, Villupuram, Cuddalore (Tamil Nadu), Chittoor (Andhra Pradesh), and Puducherry reported the highest percent positivity. These districts consistently reported high positivity rates throughout the study period. Person distribution Among AES cases tested for JE, 38,793 (60%) were male and 26,211 (40%) were female, with an equal JE positivity rate of 10% in both groups. The highest number of samples was from individuals aged 10–19 years (11,335; 17.4%). Of the 65,066 cases tested for JE, 6,540 (10.1%) were positive for JEV IgM by ELISA. Fever was the most common clinical feature, present in 56,653 cases (87.2%), followed by seizures in 24,308 cases (37.4%) and altered sensorium in 18,616 cases (28.7%). Comparing 2014–2018 and 2019–2023, JE positivity increased by 3.1% among children under 10 years and decreased by 2% in the 51–60-year age group.(Fig. 4). The highest percent positivity was observed in the 80–90 years age group in the central zone (33.3%), the 30–40 years age group in the north zone (4.5%), and the 10–20 years age group in the east zone (13%), northeast zone (26.9%), south zone (11.3%), and west zone (27.8%).Among the JE cases, positivity was highest among children aged 6–14 years (13.8%), followed by those aged 45 years and above (11.7%). Both males (10.1%) and females (10.1%) had an identical positivity rate (Supplementary Table 1). Age structure of JE cases during 2014-18 compared with 2019–2023, VRDLN, India, 2014–2023 (N = 65066) Figure 5 presents the observed and adjusted trends in JE positivity (Panel A), positive case counts (Panel B), and total tests conducted (Panel C) over time (2014–2023). The adjusted positivity trend, after removing seasonality and normalizing for the number of laboratories, shows a smoother, long-term decline over the study period. The observed positive case counts show sharp peaks, with a particularly prominent increase in 2019–2020, the adjusted positive count smooths these spikes, suggesting a broader cyclical pattern of case burden. The adjusted test count accounts for the number of reporting labs, showing periodic variations but a relatively stable trend over time. A distinct decline in testing is seen in 2020, coinciding with the COVID-19 pandemic and the test count is starting to rise post 2023. Time series plot showing adjusted positivity, positive cases and test counts for JE from 2014–2023 Discussion We examined the epidemiology of AES and JE cases reported through the VRDL network in India from 2014 to 2023, making this the first study to analyze 10 years of AES and JE data from the VRDLN since its inception. The VRDLN has significantly enhanced India’s surveillance capacity, ensuring the timely identification and containment of outbreaks, particularly in the face of emerging and re-emerging infectious threats. Over the ten years, the network reported approximately 10 lakh AES cases, with over 50% tested for JE. Before the establishment of VRDLs, India lacked sufficient capacity for testing viral pathogens and a centralized mechanism to aggregate and analyze etiological data. With the establishment of VRDLs, testing capabilities have expanded to include over 70 pathogens, accompanied by improved geographical coverage of endemic areas and the systematic collection of clinical and epidemiological data to inform public health policies and interventions. The significant increase in AES case testing—rising sixfold between 2014 and 2019—reflects this progress. The study highlights a few important findings and implications. The positivity rate for AES cases in the VRDLs was 16.3%, lower than the 28.8% reported in a South Indian study [4]. This discrepancy may stem from VRDLs not routinely testing for bacterial, fungal, and non-infectious causes of AES. The ongoing transition of VRDLs to Infectious Diseases Research and Diagnostic Laboratories (IRDLs) offers a promising opportunity to expand testing capabilities to include bacterial, mycological, and parasitological etiologies [21]. Moreover, inconsistent use of case definitions, suboptimal sample collection and transportation, and deviations from testing algorithms might have further contributed to the lower positivity rates. The co-infections identified in our analysis were like previously reported from India [4, 22]. Variations in findings across studies may be attributed to several factors: (1) Our study focused exclusively on viral pathogens, whereas some other studies included a broader range of etiologies, including bacterial and parasitic infections; (2) Temporal shifts in epidemiology, which may influence disease burden and pathogen distribution over time; and (3) Differences in testing algorithms, case definitions, and surveillance methodologies, which can impact case detection rates and overall findings. These factors limit direct comparability between studies and highlight the importance of standardized surveillance approaches. Among AES cases, positivity was highest for dengue virus, followed by chikungunya virus and JE virus. This finding contrasts with studies from other regions of India, where JE virus was the predominant etiological agent [4, 23, 24]. The increased reporting of JE cases facilitated by VRDLs indicates a previously undetected burden of the disease, emphasizing the need for enhanced surveillance efforts. Though JEV is the most common cause of AES all over India, emerging viral threats such as West Nile virus (WNV), Chandipura virus (CHPV), Kyasanur Forest Disease (KFD), Human enterovirus (EV), Nipah virus and other novel arboviruses pose an increasing risk, contributing to the evolving epidemiology of AES in India [25]. Enhanced surveillance, early diagnostic capabilities, and a One Health approach are crucial to identifying and mitigating the impact of these emerging pathogens. JE positivity was equally distributed between males and females in this study, diverging from earlier research that reported higher positivity among males due to their greater exposure to vectors during outdoor activities [26, 27]. The large, nationally representative sample size in our study likely minimized the gender disparities observed in earlier institution-based studies. Many studies conducted previously in India have identified co-infection of JE with other pathogens [7, 10, 22, 28]. The predominant co-circulation of flaviviruses (JEV, dengue, Chikungunya) in our study suggests overlapping transmission dynamics facilitated by shared mosquito vectors, reinforcing the necessity for integrated vector control strategies. The other coinfections of JE with varicella, measles, Scrub typhus, EBS etc. highlights the complexity of AES etiology and the need for multi-pathogen diagnostic approaches in endemic settings. JE is primarily transmitted by Culex mosquitoes, which breed in water bodies with abundant vegetation, particularly in rice fields. The abundance of these vectors is closely linked to rice cultivation, shallow ditches, and standing water pools, creating ideal breeding sites. Ecological factors, such as changes in land use, expansion of rice paddies, and deforestation, may influence mosquito populations and, consequently, JE transmission dynamics [29, 30]. The regions consistently reporting high JE positivity in our study correspond to areas with a high density of such vector breeding habitats. In addition to ecological drivers, variations in JE vaccination coverage across endemic districts may contribute to differences in positivity rates. Some regions may have higher susceptibility due to lower vaccine uptake or gaps in immunization programs, which could result in higher case numbers. Furthermore, enhanced testing and reporting in these regions, particularly following the establishment of VRDLs, may lead to increased case detection, influencing observed JE positivity rates. Currently, the inactivated SA 14-14-2 JE vaccine (JEEV®) and the inactivated Vero cell culture-derived Kolar strain (821564XY) JE vaccine (JENVAC®) are administered in a two-dose regimen at 9 months and between 16 and 24 months of age to children in endemic districts as part of UIP and adult vaccination using JENVAC vaccine in 42 districts of Assam, Uttar Pradesh and West Bengal [31]. A recent study conducted in the endemic districts of Maharashtra and Telangana has reported a reduction in annual AES and JE incidence in these vaccinated districts [15]. However, in our study we report and increase in percent positivity among children under 10 years old from 2019 to 23. The observed shift in JE distribution toward younger age groups across the two time periods cannot be directly attributed to vaccine coverage for two key reasons: (a) our laboratory network does not collect data on vaccination status, and (b) our study period (2014–2023) falls entirely within the post-vaccination phase, with no pre-vaccination data available for comparison. Consequently, we were unable to assess the specific factors driving this shift. This may also be due to the fact that clinically diagnosed cases referred to the VRDLs are only getting tested for JE. Strengths and limitations One of the study’s key strengths is the large dataset, comprising approximately 10 lakh AES cases over a decade, which provides a robust basis for understanding the epidemiological trends of AES and JE in India. The VRDLs’ nationwide distribution, particularly in endemic districts, ensures comprehensive geographical representation, allowing the identification of regional patterns and hotspots. This study offers a decade-long, comprehensive evaluation into the etiology of Acute Encephalitis Syndrome (AES). By examining fluctuations in positivity rates over time, it provides valuable insights into the evolving epidemiology of AES & JE. The study also maps the geographical distribution of testing rates and JE positivity, highlighting regional patterns. A key breakthrough is the exploration of coinfections among AES patients—an aspect largely overlooked in previous surveillance studies. By uncovering the coexistence of multiple pathogens, this study enhances the understanding of AES/JE, laying the foundation for more effective disease control and prevention strategies. The study also demonstrates the utility of VRDLs in capturing the epidemiological landscape of AES and JE, highlighting their importance in India’s infectious disease surveillance framework. However, our analysis has certain limitations. Since the data were derived from cases reported to VRDLs, it does not allow for estimating the population-level burden of AES and JE. Another limitation of this study is the absence of individual vaccination status data for JE cases. The VRDL network primarily functions as a laboratory surveillance system and does not routinely capture immunization histories of tested individuals. This restricts our ability to assess vaccine effectiveness, identify breakthrough infections, or determine the proportion of JE cases occurring in vaccinated versus unvaccinated individuals. Factors such as variations in vaccine uptake, delays in administration, and differences in immunization strategies across regions could influence JE trends but cannot be accounted for in our analysis. Although VRDLs adhere to SOPs and undergo regular training, variations in algorithmic testing patterns and testing kits may exist across some labs, potentially influencing the observed AES and JE positivity patterns in our study. However, these differences likely reflect real-world variations in testing practices, offering a pragmatic view of the epidemiology of these infections. Among these variations, the application of the AES case definition is likely the least affected, reinforcing our confidence in the reliability and validity of our findings. Furthermore, surveillance-based case detection inherently introduces biases, as severe or hospitalized cases are more likely to be captured, whereas milder or asymptomatic JE infections especially in vaccinated individuals may go undiagnosed. The unavailability of clinical outcome data also restricts the ability to measure pathogen virulence and the overall impact of the disease. Future studies incorporating vaccination history, seroprevalence surveys, and regional vaccine coverage data would be critical in further elucidating the impact of JE immunization programs on disease trends in India. Conclusions and recommendations The study underscores the importance of strengthening adherence to standardized case definitions and testing protocols at referring healthcare facilities. Such measures will improve diagnostic accuracy, enhance pathogen detection, and contribute to early warning and response systems. While JE vaccination and vector control programs remain central to disease prevention, the presence of other causative agents for AES highlights the need for a collaborative, multi-pathogen surveillance approach. Finally, there is a pressing need to transition from JE-focused surveillance to a comprehensive system that captures the entire etiology matrix of AES. Such an approach would enable policymakers and healthcare professionals to plan and implement evidence-based public health strategies, addressing the broader spectrum of causes and ensuring better disease control and management. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Acknowledgements Arpna Srivastava1, Kamal Singh1, Shiwangi Gupta1, Ravi Muthusamy2, Kalaivani Sekar2, Thambithurai Boopathy2, Swetha Durai2, Shankar Vidhate3, Rashmi Gunjikar3, Asha Salunke 3, Rashi Srivastava3, Kirtee Khutwad3, Pradnya Shinde3, Muruganandan Nagarajan4, Sivamma BV5, Usha Kalawat6, Sarada Dulla7, P. V. Prasanna Kumar8, C. Siva Kalyani9, Sumit Rai10, Bathala Nagasrilatha11, Boyapalli Shanti Reddy12, Nagajyothi Beldonu13, Mika Umpo14, Biswa Jyoti Borkakoti15, Ajanta Sharma16, Angshurekha Das17, Debadatta Dhar Chanda18, Samrat Biswas19, Sanjay Bhattacharya20, Pallabi Sargiary21, DeepJyoti Kalita22, Jashbeer Singh Roy23, Lahari Saikia24, Binod Kumar Pati25, Ganesh Chandra Sahoo26, Vijay Kumar27, Kanhaiya Jha28, Poonam Kumari29, Ashif Ali Hashan30, Radha Kanta Ratho31, Varsha Gupta32, Anudita Bhargava33, Debashish Samal34, Nikita Sherwani35, Rekha Barapatre36, Erumalla Naveen37, Richa Anjleen Tigga38, Aashish Choudhary39, Sonal Saxena40, Mala Chabbra41, Manoj Jais42, Charu Jain43, Santosh Karade44, Madhu Khanna45, Anita Sandhya Estibeiro46, Neeta Khandelwal47, Summaiya Mullan48, Madhulika Mistry49, Hiral M Gadhavi50, Govind Ninama51, Kairavi J Desai52, Ashwini Agarwal53, Paramjeet Gill54, Surinder Kumar55, Prerna Aggarwal56, Priti Agarwal57, Santwana Verma58, Anuradha Sood59, Ramesh Chander Guleria60, Sridhar Rao61, Bashir Ahmed Fomda62, Sandeep Dogra63, Asifa Nazir64, Junaid Ahmad65, Abiroo Jan66, Suman Kumar67, Manoj Kumar68, Preeti Mohan Kumar69, GB Shantala70, Mallikarjun Koppad71, Krishna S72, Amurtha Kumari B73, Mahesh Kumar S74, HG Sreedhara75, Sunil Kumar Biradar76, Kamran Zaman77, Reeta S. Mani78, Nazeema Tabaseera79, Anitha Puduvail Moorkoth80, Balakrishnan Anukumar81, Pushpa Kizhakkekarammel82, Saritha N83, Kalpana George84, Raji TK85, Joana Mary Magdaline86, Kavita Raja87, Debasis Biswas88, Pushpendra Singh89, Amresh Nigudgi90, Vaibhav Mishra91, Sumit Kumar Rawat92, Manish Purohit93, Prafulla Songara94, R. Mahesh Reddy95, Vaishali Rahangdale96, Jyoti Iravane97, Vijay Kumar Chincholkar98, Neeta P. Jangale99, Gita Nataraj100, Meena Mishra101, Nayana Ingole102, Rupali S Mantri103, Dilip Gedam104, Madhuri Magan Suryawanshi105, Heigrujam Rebachandra Singh106, Rajkumar Manojkumar Singh107, Annie Bakorlin Khyriem108, Swagnik Roy109, Ira Prahraj110, Baijayantimala Mishra111, Bhabani Patnaik112, Susmita Kumari Sahu113, Sanghamitra Padhi114, Dipankar Pattanik115, Rahul Dhodapkar116, Sampath Srinivasan117, Kanwardeep Dhingra118, Rupinder Bakshi119, Shipra Galhotra120, Kamla Kant121, Ritu Garg122, Ravisekhar Gadepalli123, Bharti Malhotra124, Anshu Sharma125, Anjli Gupta126, Rajesh Bansal127, Naveen Saxena128, Prabhu Prakash129, Ashish Bahal130, Kaveri Krishnasamy131, Bharathi Santhose N.132, Sundarajan Thangavel133, C Sugumari134, Santhana Kumarasamy Poongodi135, G. Sucila Thangam136, Navaneetha Krishnan Ratnapriya137, K Girija138, Luke Elizabeth Hanna139, C Nithya140, JK Surekha141, V Sudha Rani142, Rahul Narang143, N Srinivas144, Tapan Majumdar145, Shruti Radera146, Gaurav Raj Dwivedi147, Gopal Nath148, Shefali Gupta149, Varun Goel150, Nazish Fatima151, Rajesh Kumar Verma152, Amit Garg153, Atul Garg154, Yogendra Pratap Mathuria155, Umesh156, Shalabh Jauhari157, Mamta Chawla Sarkar158, Raja Ray159, Ranadeep Ghosh160, Nandita Pal161, Reena Ray Ghosh162, Sayantan Banerjee163, Arunabhao Sarkar164, Bipasa Chakraborty165, Asis Manna166, Tanusri Biswas167, Shahina Mustaqim168. 1Department of Health Research, New Delhi 2ICMR-National Institute of Epidemiology, Chennai, Tamil Nadu, India 3ICMR-National Institute of Virology, Pune 4ICMR-Regional Medical Research Centre, Sri Vijaya Puram, Andaman and Nicobar Islands 5Guntur Medical College, Guntur, Andhra Pradesh 6Sri Venkateswara Institute of Medical Sciences, Tirupati, Andhra Pradesh 7Siddhartha Medical College, Vijayawada, Andhra Pradesh 8Ranga Raya Medical College, Kakinada, Andhra Pradesh 9Andhra Medical College, Vishakhapatnam, Andhra Pradesh 10All India Institute of Medical Sciences, Mangalagiri, Andhra Pradesh 11Rajiv Gandhi Institute of Medical Sciences, Kadapa, Andhra Pradesh 12Government Medical College, Anantapur, Andhra Pradesh 13Government Medical College, Kurnool, Andhra Pradesh 14Tomo Riba Institute Health and Medical Sciences, Naharlagun, Arunachal Pradesh 15ICMR-Regional Medical Research Centre, Dibrugarh, Assam 16Gauhati Medical College, Guwahati, Assam 17Jorhat Medical College, Jorhat, Assam 18Silchar Medical College, Silchar, Assam 19Tezpur Medical College, Tezpur, Assam 20Fakhruddin Ali Ahmed Medical College, Barpeta, Assam 21Diphu Medical College & Hospital, Diphu, Assam 22All India Institute of Medical Sciences, Guwahati, Assam 23Lakhimpur Medical College, Chowkham, Assam 24Nagaon Medical College & Hospital, Nagaon, Assam 25All India Institute of Medical Sciences Patna, Bihar 26ICMR-Rajendra Memorial Research Institute of Medical Sciences, Patna, Bihar 27Patna Medical College, Patna, Bihar 28Darbhanga Medical College, Darbhanga, Bihar 29Shree Krishna Medical College, Muzaffarpur, Bihar 30Jawaharlal Nehru Medical College & Hospital, Bhagalpur, Bihar 31Post Graduate Institute of Medical Education & Research, Chandigarh 32Government Medical College & Hospital, Chandigarh 33All India Institute of Medical Sciences, Raipur, Chhattisgarh 34Late Baliram Kashyap Memorial Government Medical College, Jagdalpur, Chhattisgarh 35Pandit Jawaharlal Nehru Memorial Medical College, Raipur, Chhattisgarh 36Chhattisgarh Institute of Medical Sciences, Bilaspur, Chhattisgarh 37Late Shrimati Indira Gandhi Memorial Government Medical College, Kanker, Chhattisgarh 38Chandulal Chandrakar Memorial Government Medical College, Durg, Chhattisgarh 39All India Institute of Medical Sciences, New Delhi 40Maulana Azad Medical College, New Delhi 41Dr. Ram Manohar Lohia Hospital and Atal Bihari Vajpayee Institute of Medical Sciences, New Delhi 42Lady Hardinge Medical College, New Delhi 43University College of Medical Sciences & Guru Teg Bahadur Hospital, New Delhi 44Army Hospital Research and Referral, Dhaula Kuan, New Delhi 45Vallabhbhai Patel Chest Institute, University of Delhi, New Delhi 46Goa Medical College, Bambolim, Goa 47B.J. Medical College, Ahmedabad, Gujarat 48Government Medical College, Surat, Gujarat 49Pandit Dindayal Upadhyay Medical College, Rajkot, Gujarat 50Shri Meghji Pethraj(MP) Shah Medical College, Jamnagar, Gujarat 51Government Medical College, Vadodara, Gujarat 52Government Medical College, Bhavnagar, Gujarat 53All India Institute of Medical Sciences, Rajkot, Gujarat 54Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences, Rohtak, Haryana 55Bhagat Phool Singh Government Medical College for Women, Sonepat, Haryana 56Kalpana Chawla Government Medical College, Karnal, Haryana 57All India Institute of Medical Science, Bilaspur, Himachal Pradesh 58Indira Gandhi Medical College, Shimla, Himachal Pradesh 59Dr. Rajendra Prasad Government Medical College, Tanda, Himachal Pradesh 60Shri Lal Bahadur Shashtri Government Medical College, Mandi, Himachal Pradesh 61Pandit Jawaharlal Nehru Government Medical College, Chamba, Himachal Pradesh 62Sher-i-Kashmir Institute of Medical Sciences, Srinagar, Jammu & Kashmir 63Government Medical College, Jammu, Jammu & Kashmir 64Government Medical College, Srinagar, Jammu & Kashmir 65Government Medical College, Baramulla, Jammu & Kashmir 66Government Medical College, Anantnag, Jammu & Kashmir 67All India Institute of Medical Sciences, Deogarh, Jharkhand 68Rajendra Institute of Medical Sciences, Ranchi, Jharkhand 69Mahatma Gandhi Memorial Medical College, Jamshedpur, Jharkhand 70Bangalore Medical College & Research Institute, Bangalore, Karnataka 71Shimoga Institute of Medical Sciences, Shivamogga, Karnataka 72Vijayanagar Institute of Medical Science, Bellary, Karnataka 73Mysore Medical College & Research Institute, Mysuru, Karnataka 74Karnataka Medical College & Research Institute, Hubballi, Karnataka 75Hassan Institute of Medical Sciences, Hassan, Karnataka 76Gulbarga Institute of Medical Sciences, Kalaburagi, Karnataka 77ICMR-National Institute of Traditional Medicine, Belagavi, Karnataka 78National Institute of Mental Health & Neurosciences, Bangalore, Karnataka 79Kodagu Institute of Medical Sciences, Madikeri, Karnataka 80Government Medical College, Kozhikode, Kerala 81ICMR-National Institute of Virology Kerala Unit, Alappuzha, Kerala 82Government Medical College, Thrissur, Kerala 83Government Medical College, Thiruvananthapuram, Kerala 84Government Medical College, Kannur, Pariyaram, Kerala 85Government Medical College, Manjeri, Malapuram, Kerala 86Government Medical College, Ernakulam, Kerala 87Sree Chitra Tirunal Institute for Medical Sciences & Technology, Thiruvananthapuram, Kerala 88All India Institute of Medical Sciences, Bhopal, Madhya Pradesh 89ICMR-National Institute for Research in Tribal Health, Jabalpur, Madhya Pradesh 90Shyam Shah Medical College, Rewa, Madhya Pradesh 91Gajra Raja Medical College, Gwalior, Madhya Pradesh 92Bundelkhand Medical College, Sagar, Madhya Pradesh 93Mahatma Gandhi Memorial Medical College, Indore, Madhya Pradesh 94Dr. Laxmi Narayan Pandey Government Medical College, Ratlam, Madhya Pradesh 95Armed Forces Medical College, Pune, Maharashtra 96Government Medical College, Nagpur, Maharashtra 97Government Medical College, Chhatrapati Sambhajinagar, Maharashtra 98Dr Vaishampayan Memorial Government Medical College, Solapur, Maharashtra 99Government Medical College, Miraj, Maharashtra 100Seth Gordhandas Sunderdas (GS) Medical College & King Edward Memorial (KEM) Hospital, Mumbai, Maharashtra 101All India Institute of Medical Sciences, Nagpur, Maharashtra 102Kasturba Hospital for Infectious Diseases, Mumbai, Maharashtra 103Government Medical College, Akola, Maharashtra 104Indira Gandhi Government Medical College, Nagpur, Maharashtra 105Shri Bhausaheb Hire Government Medical College, Dhule, Maharashtra 106Regional Institute of Medical Sciences, Imphal, Manipur 107Jawaharlal Nehru Institute of Medical Sciences, Imphal, Manipur 108North Eastern Indira Gandhi Regional Institute of Health & Medical Sciences, Shillong, Meghalaya 109Zoram Medical College, Zoram, Mizoram 110ICMR-Regional Medical Research Centre, Bhubaneswar, Odisha 111All India Institute of Medical Sciences, Bhubaneswar, Odisha 112Srirama Chandra Bhanja Medical College, Cuttack, Odisha 113Saheed Laxman Nayak Medical College & Hospital, Koraput, Odisha 114Maharaja Krushna Chandra Gajapati Medical College, Brahmapur, Odisha 115Veer Surendra Sai Institute of Medical Sciencves and Reserach, Sambalpur, Odisha 116Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry 117Indira Gandhi Medical College & Research Institute, Puducherry 118Government Medical College, Amritsar, Punjab 119Government Medical College, Patiala, Punjab 120Guru Gobind Singh Medical College, Faridkot, Punjab 121All India Institute of Medical Sciences, Bathinda, Punjab 122Dr. B.R. Ambedkar State Institute of Medical Sciences, Mohali, Punjab 123All India Institute of Medical Sciences, Jodhpur, Rajasthan 124Sawai Man Singh(SMS) Medical College, Jaipur, Rajasthan 125Rabindranath Tagore Medical College, Udaipur, Rajasthan 126Sardar Patel Medical College, Bikaner, Rajasthan 127Jhalawar Medical College, Jhalawar, Rajasthan 128Government Medical College, Kota, Rajasthan 129SN Medical College, Jodhpur, Rajasthan 130Military Hospital Jodhpur, Rajasthan 131King Institute of Preventive Medicine and Research, Chennai, Tamil Nadu 132Coimbatore Medical College, Coimbatore, Tamil Nadu 133Government Mohan Kumaramangalam Medical College, Salem, Tamil Nadu 134Madurai Medical College, Madurai, Tamil Nadu 135Tirunelveli Medical College, Tirunelveli, Tamil Nadu 136Government Medical College, Theni, Tamil Nadu 137Madras Medical College, Chennai, Tamil Nadu 138Government Thiruvarur Medical College, Thiruvarur, Tamil Nadu 139ICMR-National Institute for Research in Tuberculosis, Chennai, Tamil Nadu 140Government Viluppuram Medical College, Villupuram, Tamil Nadu 141Gandhi Medical College, Secunderabad, Hyderabad, Telangana 142Osmania Medical College, Hyderabad, Telangana 143All India Institute of Medical Sciences, Bibinagar, Telangana 144Kakatiya Medical College, Nizampura, Warangal, Telangana 145Agartala Government Medical College, Agartala, Tripura 146King George’s Medical University, Lucknow, Uttar Pradesh 147ICMR-Regional Medical Research Center, Gorakhpur, Uttar Pradesh 148Banaras Hindu University, Varanasi, Uttar Pradesh 149All India Institute of Medical Science, Raebareli, Uttar Pradesh 150Government Institute of Medical Sciences, Greater Noida, Uttar Pradesh 151Jawaharlal Nehru Medical College, Aligarh, Uttar Pradesh 152Uttar Pradesh University of Medical Sciences, Saifai, Uttar Pradesh 153Lala Lajpat Rai Memorial Medical College, Meerut, Uttar Pradesh 154Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, Uttar Pradesh 155All India Institute of Medical Sciences, Rishikesh, Uttarakhand 156Government Medical College, Haldwani, Uttarakhand 157Government Doon Medical College, Dehradun, Uttarakhand 158ICMR-National Institute for Research in Bacterial Infections Kolkata, West Bengal 159Institute of Post Graduate Medical Education & Research, Kolkata, West Bengal 160Midnapore Medical College & Hospital, Midnapore, West Bengal 161Malda Medical College, Malda, West Bengal 162Diamond Harbour Government Medical College & Hospital, Diamond Harbour, West Bengal 163All India Institute of Medical Sciences, Kalyani, West Bengal 164North Bengal Medical College, Darjeeling, West Bengal 165Radha Gobinda Kar Medical College, Kolkata, West Bengal 166Murshidabad Medical College & Hospital, Murshidabad, Berhampore, West Bengal 167Burdwan Medical College, Burdwan, West Bengal 168Andaman and Nicobar Island Institute of Medical Sciences, Sri Vijaya Puram, Andaman and Nicobar Islands Abbreviations Acute Encephalitis Syndrome Japanese Encephalitis Virus Virus Research and Diagnostic Laboratory Network Integrated Disease Surveillance Programme of India Enzyme Linked Immunosorbent Assay Polymerase Chain Reaction Cerebro Spinal Fluid Infectious Diseases Research and Diagnostic Laboratory Author contributions RSA: Conceptualization, methodology, investigation, writing-review and editing, funding acquisition. SR: Software, validation, investigation, writing-review and editing. RSV: Methodology, investigation, formal analysis, writing-original draft, writing-review and editing. SSP: Methodology, investigation, software, formal analysis, data curation, visualisation. VR: Methodology, investigation, formal analysis, writing-original draft. MVM: Conceptualization, methodology, writing-review and editing, funding acquisition, supervision. Funding The study was funded by Department of Health Research under the scheme “Prevention & control of diseases- Development of tools to prevent outbreak of epidemics”. Grant in aid No: R.15013/04/2021-HR-VRDL. Data availability The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request. Declarations Ethics approval and consent to participate This study was performed in line with the principles of the Declaration of Helsinki. Ethical approval was obtained from the Institutional Human Ethics Committee of ICMR-NIE, Chennai. Approval no: NIE/IHEC/201606-01 dated 29/07/2024. As this study was a secondary data analysis of routinely reported surveillance data through the VRDLN, informed consent from each patient was not taken. All data used in the analysis were de-identified and coded to ensure confidentiality. Consent to publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Contributor Information Manoj V. Murhekar, Email: mmurhekar@gmail.com VRDLN: Arpna Srivastava, Kamal Singh, Shiwangi Gupta, Ravi Muthusamy, Kalaivani Sekar, Thambithurai Boopathy, Swetha Durai, Shankar Vidhate, Rashmi Gunjikar, Asha Salunke, Rashi Srivastava, Kirtee Khutwad, Pradnya Shinde, Muruganandan Nagarajan, Shahina Mustaqim, B. V. Sivamma, Usha Kalawat, Sarada Dulla, Prasanna Kumar, Siva Kalyani, Sumit Rai, Bathala Nagasrilatha, Boyapalli Shanti Reddy, Nagajyothi Beldonu, Mika Umpo, Biswa Jyoti Borkakoti, Ajanta Sharma, Angshurekha Das, Debadatta Dhar Chanda, Samrat Biswas, Sanjay Bhattacharya, Pallabi Sargiary, DeepJyoti Kalita, Jashbeer Singh Roy, Lahari Saikia, Binod Kumar Pati, Ganesh Chandra Sahoo, Vijay Kumar, Kanhaiya Jha, Poonam Kumari, Ashif Ali Hashan, Radha Kanta Ratho, Varsha Gupta, Anudita Bhargava, Debashish Samal, Nikita Sherwani, Rekha Barapatre, Erumalla Naveen, Richa Anjleen Tigga, Aashish Choudhary, Sonal Saxena, Mala Chabbra, Manoj Jais, Charu Jain, Santosh Karade, Madhu Khanna, Anita Sandhya Estibeiro, Neeta Khandelwal, Summaiya Mullan, Madhulika Mistry, Hiral M. Gadhavi, Govind Ninama, Kairavi J. Desai, Ashwini Agarwal, Paramjeet Gill, Surinder Kumar, Prerna Aggarwal, Priti Agarwal, Santwana Verma, Anuradha Sood, Ramesh Chander Guleria, Sridhar Rao, Bashir Ahmed Fomda, Sandeep Dogra, Asifa Nazir, Junaid Ahmad, Abiroo Jan, Suman Kumar, Manoj Kumar, Preeti Mohan, G. B. Shantala, Mallikarjun Koppad, S. Krishna, B. Amurtha Kumari, S. Mahesh Kumar, H. G. Sreedhara, Sunil Kumar Biradar, Kamran Zaman, Reeta Mani, Nazeema Tabaseera, Anitha Puduvail Moorkoth, Balakrishnan Anukumar, Pushpa Kizhakkekarammel, N. Saritha, Kalpana George, T. K. Raji, Joana Mary Magdaline, Kavita Raja, Debasis Biswas, Pushpendra Singh, Amresh Nigudgi, Vaibhav Mishra, Sumit Kumar Rawat, Manish Purohit, Prafulla Songara, Mahesh Reddy, Vaishali Rahangdale, Jyoti Iravane, Vijay Kumar Chincholkar, Neeta Jangale, Gita Nataraj, Meena Mishra, Nayana Ingole, Rupali S. Mantri, Dilip Gedam, Madhuri Magan Suryawanshi, Heigrujam Rebachandra Singh, Rajkumar Manojkumar Singh, Annie Bakorlin Khyriem, Swagnik Roy, Ira Prahraj, Baijayantimala Mishra, Bhabani Patnaik, Susmita Kumari Sahu, Sanghamitra Padhi, Dipankar Pattanik, Rahul Dhodapkar, Sampath Srinivasan, Kanwardeep Dhingra, Rupinder Bakshi, Shipra Galhotra, Kamla Kant, Ritu Garg, Ravisekhar Gadepalli, Bharti Malhotra, Anshu Sharma, Anjli Gupta, Rajesh Bansal, Naveen Saxena, Prabhu Prakash, Ashish Bahal, Kaveri Krishnasamy, Barathi Santose, Sundarajan Thangavel, C. Sugumari, Santhana Kumarasamy Poongodi, Sucila Thangam, Navaneetha Krishnan Ratnapriya, K. Girija, Luke Elizabeth Hanna, C. Nithya, J. K. Surekha, Sudha Rani, Rahul Narang, N. Srinivas, Tapan Majumdar, Shruti Radera, Gaurav Dwivedi, Gopal Nath, Shefali Gupta, Varun Goel, Nazish Fatima, Rajesh Kumar Verma, Amit Garg, Atul Garg, Yogendra Pratap Mathuria, Umesh, Shalabh Jauhari, Mamta Chawla Sarkar, Raja Ray, Ranadeep Ghosh, Nandita Pal, Reena Ray Ghosh, Sayantan Banerjee, Arunabhao Sarkar, Bipasa Chakraborty, Asis Manna, and Tanusri Biswas References Associated Data Supplementary Materials Supplementary Material 1 Data Availability Statement The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.